NGEN · NervGen Pharma Corp. Common stock

Summary

This SEC Filing is a Form 40-F Annual Report submitted by NervGen Pharma Corp. (NGEN) for the fiscal year ended December 31, 2025. As a Canadian foreign private issuer, the company utilizes this form to comply with SEC reporting requirements under the Securities Exchange Act of 1934. The filing encompasses comprehensive financial statements prepared in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board. Key operational highlights for the year include a significant private placement financing completed in November 2025, involving the issuance of common shares and warrants. The document details the company's research and development activities, specifically breaking down expenses related to preclinical development, clinical and regulatory operations, and chemistry manufacturing controls. Additionally, the filing outlines executive compensation structures, stock option activities with various exercise price ranges, and the utilization of an At-The-Market (ATM) equity program. The report also addresses the company's tax credit positions in Canada, including Scientific Research and Experimental Development (SR&ED) investment tax credits. Corporate governance changes are noted, including the appointment of a new President and Chief Executive Officer effective January 2026.

Key takeaways

• Completed a private placement financing in November 2025, issuing shares and warrants to support operations.
• Significant investment in R&D with detailed expense categorization including preclinical, clinical, and CMC activities.
• Executive leadership transition announced with a new President and CEO appointed effective January 2026.